Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19

The Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to COVID-19 (ANA-COVID-GEAS) was conducted to assess the efficacy and safety of anakinra vs standard of care alone for patients with severe COVID-19 pneumonia and hyperinflammation. Key takeaways: 1. COVID-19 pneumonia is often associated with hyperinflammation, and the efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation were unclear. 2. The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-to-treat basis. 3. The study found that anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia. 4. The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups, and there was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15.